European Urology

@EUplatinum

The Platinum Journal | Official Journal of EAU | Ranked #1 in Urology & Nephrology | Editor | IF 17.581

Vrijeme pridruživanja: travanj 2011.

Tweetovi

Blokirali ste korisnika/cu @EUplatinum

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @EUplatinum

  1. prije 13 sati

    February 2020 Issue Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer

    Poništi
  2. prije 20 sati

    Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort

    Poništi
  3. 2. velj

    Climbing over the Barriers of Current Imaging Technology in Urology

    Poništi
  4. 1. velj

    Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 1: Acquisition

    Poništi
  5. 1. velj

    February 2020 Issue The Complex and Nuanced Care for Early-stage Testicular Cancer: Lessons from the European Association of Urology and American Urological Association Testis Cancer Guidelines

    Poništi
  6. 31. sij

    February 2020 Issue: Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials: Editorial:

    Poništi
  7. 30. sij

    February 2020 Issue: Long-term Risk of Recurrence in Surgically Treated Renal Cell Carcinoma: A Post Hoc Analysis of the Eastern Cooperative Oncology Group—American College of Radiology Imaging Network E2805 Trial Cohort

    Poništi
  8. 30. sij

    Platinum Editorial from Marko Babjuk: Are the Role of Surgery and its Complications Sufficiently Focused in the Era of Perioperative Systemic Treatments?

    Poništi
  9. 30. sij

    Platinum Editorial from Treatment Choices for Front-line Metastatic Clear Cell Renal Cancer

    Poništi
  10. 28. sij
    , , i još njih 5
    Poništi
  11. 27. sij

    February 2020 Issue: Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial

    Poništi
  12. 26. sij

    Efficacy, safety, and tolerability of mirabegron in patients aged ≥65 yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR) Editorial from and

    Poništi
  13. 25. sij

    European Association of Urology Guidelines Office: How We Ensure Transparent Conflict of Interest Disclosure and Management

    Poništi
  14. 25. sij

    Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies

    Poništi
  15. 24. sij

    Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study: Editorial from :

    Poništi
  16. 24. sij

    Platinum Editorial from Andre Luis Abreu: The Pillars for Sustained Growth of Magnetic Resonance Imaging Pathway for Prostate Cancer Diagnosis: Quality, Reproducibility, Accessibility, Cost Effectiveness, and Training

    Poništi
  17. 23. sij

    The New Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting Database: Opportunities and Limitations

    Poništi
  18. 22. sij

    Words of Wisdom from Steven C. Campbell, Yun-Lin Ye, Zhiling Zhang, Joseph Zabell Re: Impact of Acute Kidney Injury and its Duration on Long-term Renal Function after Partial Nephrectomy

    Poništi
  19. 22. sij

    EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort

    Poništi
  20. 21. sij

    February 2020 Issue: Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in CRPC: Editorial:

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·